Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells. This study will utilize a staggered enrollment design with a safety observation period.

Trial Details

NCT ID
NCT06227026
Phase
PHASE1
Sponsor
University of Utah
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Anti-CD19 CAR-T cells
Locations (sample)
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Subjects aged ≥ 18 years.
  • Histologically confirmed relapsed or refractory CD-19+ malignancy, including: non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), Chron…
  • Subjects who have relapsed or refractory disease after failing at least 2 or more prior lines of therapy.
  • ECOG Performance Status ≤ 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →